Compounds > aica ribonucleotide

aica ribonucleotide and ER-Negative PR-Negative HER2-Negative Breast Cancer

aica ribonucleotide has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Assaiya, A; Jaiswal, P; Kumar, J; Parmar, HS; Tripathi, V1

Other Studies

1 other study(ies) available for aica ribonucleotide and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
Anti-cancer Effects of 5-Aminoimidazole-4-Carboxamide-1-β-D-Ribofuranoside (AICAR) on Triple-negative Breast Cancer (TNBC) Cells: Mitochondrial Modulation as an Underlying Mechanism.
    Current cancer drug targets, 2022, Volume: 22, Issue:3

    Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Doxorubicin; Humans; Imidazoles; Mitochondria; Ribonucleotides; Transcription Factors; Triple Negative Breast Neoplasms

2022